An Open-Label Randomized Phase II Study of Combining Osimertinib with and without Ramucirumab in TKI-na ve EGFR-mutant Locally Advanced or Metastatic NSCLC
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
